These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 24305455)
1. Administration of glucocorticoids in boys with Duchenne muscular dystrophy. Gutierrez A; England JD Continuum (Minneap Minn); 2013 Dec; 19(6 Muscle Disease):1703-8. PubMed ID: 24305455 [TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Manzur AY; Kuntzer T; Pike M; Swan A Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031 [TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Manzur AY; Kuntzer T; Pike M; Swan A Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215 [TBL] [Abstract][Full Text] [Related]
4. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H; Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484 [TBL] [Abstract][Full Text] [Related]
5. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy. Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116 [TBL] [Abstract][Full Text] [Related]
6. Corticosteroids for the treatment of Duchenne muscular dystrophy. Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418 [TBL] [Abstract][Full Text] [Related]
7. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy. Buyse GM; Goemans N; van den Hauwe M; Meier T Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412 [TBL] [Abstract][Full Text] [Related]
8. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment. Tung JY; Lam TP; Chan SH J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004 [TBL] [Abstract][Full Text] [Related]
9. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial. Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ; JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703 [TBL] [Abstract][Full Text] [Related]
11. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653 [TBL] [Abstract][Full Text] [Related]
12. Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations. Bowden SA; Connolly AM; Kinnett K; Zeitler PS J Neuromuscul Dis; 2019; 6(1):31-41. PubMed ID: 30614808 [TBL] [Abstract][Full Text] [Related]
13. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Hoffman EP; Schwartz BD; Mengle-Gaw LJ; Smith EC; Castro D; Mah JK; McDonald CM; Kuntz NL; Finkel RS; Guglieri M; Bushby K; Tulinius M; Nevo Y; Ryan MM; Webster R; Smith AL; Morgenroth LP; Arrieta A; Shimony M; Siener C; Jaros M; Shale P; McCall JM; Nagaraju K; van den Anker J; Conklin LS; Cnaan A; Gordish-Dressman H; Damsker JM; Clemens PR; Neurology; 2019 Sep; 93(13):e1312-e1323. PubMed ID: 31451516 [TBL] [Abstract][Full Text] [Related]
14. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. Bourke JP; Bueser T; Quinlivan R Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162 [TBL] [Abstract][Full Text] [Related]
15. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Weber DR; Hadjiyannakis S; McMillan HJ; Noritz G; Ward LM Pediatrics; 2018 Oct; 142(Suppl 2):S43-S52. PubMed ID: 30275248 [TBL] [Abstract][Full Text] [Related]
16. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F; J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532 [TBL] [Abstract][Full Text] [Related]
17. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents. Herbelet S; Rodenbach A; Paepe B; De Bleecker JL Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223 [TBL] [Abstract][Full Text] [Related]
18. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F; J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964 [TBL] [Abstract][Full Text] [Related]
20. [Guideline on the use of corticosteroids in Duchenne muscular dystrophy from paediatric neurologists, neurologists and rehabilitation physicians]. de Groot IJ Ned Tijdschr Geneeskd; 2006 Mar; 150(12):684-5. PubMed ID: 16613254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]